Category: Uncategorized

CorMedix, Inc. to Report First Quarter Financial Results on May 8, 2015

Written by Welcome on May 5, 2015

BRIDGEWATER, N.J., May 5, 2015 /PRNewswire/ — CorMedix Inc. (NYSE MKT: CRMD), a…

CorMedix Presents Data from Neutrolin® Post Marketing Surveillance Study At Two Medical Conferences

Written by Welcome on April 23, 2015

BEDMINSTER, N.J., April 23, 2015 /PRNewswire/ — CorMedix Inc. (NYSE MKT: CRMD), a…

CorMedix Institutes Program to Reduce Neutrolin® Cost of Goods; Reports on Strategic Review Process Managed by Evercore

Written by Welcome on April 9, 2015

BEDMINSTER, N.J., April 9, 2015 — CorMedix Inc. (NYSE MKT: CRMD),…

CorMedix Announces Effectiveness of Registration Statements for Shares Underlying Publicly Traded Warrants

Written by Welcome on March 20, 2015

BEDMINSTER, N.J., March 20, 2015 — CorMedix Inc. (NYSE MKT:…

CorMedix Clarifies Extension of Expiration Date for Publicly Traded Warrants

Written by Welcome on March 9, 2015

BEDMINSTER, N.J., March 9, 2015 — CorMedix Inc. (NYSE MKT:…

CorMedix Inc. Provides Multiple Strategic Business Updates

Written by Welcome on March 4, 2015

–CorMedix Inc. Engages Evercore as Financial Advisor to Explore Strategic…

FDA Grants QIDP Designation to Neutrolin®, CorMedix Inc.’s Lead Product Candidate in the U.S.

Written by Welcome on January 29, 2015

BRIDGEWATER, N.J., January 29, 2015 — CorMedix Inc. (NYSE MKT:…

CorMedix Inc. Receives Fast Track Designation For Neutrolin®

Written by Welcome on January 15, 2015

BRIDGEWATER, N.J., January 15, 2015 — CorMedix Inc. (NYSE MKT:…

CorMedix Inc. Files Request with FDA for QIDP Designation for Neutrolin®

Written by Welcome on December 4, 2014

BRIDGEWATER, N.J., December 4, 2014 — CorMedix Inc. (NYSE MKT:…

Neutrolin Label Expansion Approved in Germany

Written by Welcome on December 3, 2014

BRIDGEWATER, N.J., December 3, 2014 — CorMedix Inc. (NYSE MKT:…

CorMedix Receives Approval from FDA to Initiate a Clinical Trial for Neutrolin in the US

Written by Welcome on October 24, 2014

BRIDGEWATER, N.J., October 24, 2014 — CorMedix Inc. (NYSE MKT:…

CorMedix Announces FDA IND Filing for Neutrolin® in United States

Written by Welcome on September 25, 2014

BRIDGEWATER, N.J., September 25, 2014 — CorMedix Inc. (NYSE MKT:…

Neutrolin Label Expansion Approved for the European Union

Written by Welcome on September 19, 2014

BRIDGEWATER, N.J., September 19, 2014 — CorMedix Inc. (NYSE MKT:…

FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol

Written by Welcome on August 14, 2014

BRIDGEWATER, N.J., August 14, 2014 — CorMedix Inc. (NYSE MKT:…

CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA

Written by Welcome on June 23, 2014

BRIDGEWATER, N.J., June 23, 2014 — CorMedix Inc. (NYSE MKT:…

CorMedix Awarded European Patent for Neutrolin

Written by Welcome on January 10, 2014

BRIDGEWATER, N.J., Jan. 10, 2014 /PRNewswire/ — CorMedix Inc. (NYSE MKT: CRMD), a…

CorMedix Inc. to Raise $2,000,000 in Follow on Offering

Written by Welcome on January 8, 2014

BRIDGEWATER, N.J., Jan. 8, 2014 /PRNewswire/ — CorMedix Inc. (NYSE MKT: CRMD),…